Acadia Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care Conference on March 6, 2024
29 2월 2024 - 11:05PM
Business Wire
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that
it will participate in TD Cowen’s 44th Annual Health Care
Conference on Wednesday, March 6, 2024, at 11:10 a.m. Eastern
Time.
A live webcast of Acadia’s presentation will be accessible on
the company’s website, Acadia.com, under the investors section and
an archived recording will be available on the website for
approximately one month following the presentation.
About Acadia Pharmaceuticals
Acadia is advancing breakthroughs in neuroscience to elevate
life. For 30 years we have been working at the forefront of
healthcare to bring vital solutions to people who need them most.
We developed and commercialized the first and only FDA-approved
drug to treat hallucinations and delusions associated with
Parkinson’s disease psychosis and the first and only FDA-approved
drug for the treatment of Rett syndrome. Our clinical-stage
development efforts are focused on treating the negative symptoms
of schizophrenia, Prader-Willi syndrome, Alzheimer’s disease
psychosis and multiple other programs targeting neuropsychiatric
symptoms in central nervous system disorders. For more information,
visit us at Acadia.com and follow us on LinkedIn and Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240229248127/en/
Media Contact: Acadia Pharmaceuticals Inc. Deb Kazenelson (818)
395-3043 media@acadia-pharm.com
Investor Contact: Acadia Pharmaceuticals Inc. Al Kildani (858)
261-2872 ir@acadia-pharm.com
Acadia Pharmaceuticals Inc. Jessica Tieszen (858) 261-2950
ir@acadia-pharm.com
Acadia Pharmaceuticals (NASDAQ:ACAD)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Acadia Pharmaceuticals (NASDAQ:ACAD)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024
